Abdominal aortic aneurysms: Basic mechanisms and clinical implications

Current Problems in Surgery

Volumn 39, Issue 2, 2002, Pages 110-230

  Thompson, Robert W ^a   Geraghty, Patrick J ^a   Lee, Jason K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; DOXYCYCLINE; ELASTIN; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROCOLLAGEN; PROPRANOLOL; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ABDOMINAL AORTA ANEURYSM; ANEURYSM SURGERY; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; AORTA; AORTA ATHEROSCLEROSIS; BIOMECHANICS; CLINICAL FEATURE; CONTROLLED STUDY; DEGENERATION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; FEMALE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GENETIC SUSCEPTIBILITY; HUMAN; MALE; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PHYSIOLOGY; RADIODIAGNOSIS; RAT; REVIEW; RISK ASSESSMENT; SCREENING TEST;

ANIMALS; AORTA; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; BIOMECHANICS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RATS;

EID: 0036482372     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/msg.2002.121421     Document Type: Article

References (350)

1. Resection of an aneurysm of the abdominal aorta
2. The use of tubes constructed from Vinyon "N" cloth in bridging arterial defects
3. Contribution of abdominal aortic aneurysmectomy to prolongation of life
4. Operative repair for aortic aneurysms: The gold standard
5. The Department of Veterans Affairs Aneurysm Detection and Management (ADAM) Study
6. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms
7. Recommended indications for operative treatment of abdominal aortic aneurysms
8. Vascular surgery in the United States: Workforce issues
9. Abdominal aortic aneurysm: Still missing the message
10. The influence of surgical specialty training on the outcomes of elective abdominal aortic aneurysm surgery
11. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study
12. Prevalence and associations of abdominal aortic aneurysm detected through screening
13. Abdominal aortic aneurysm in 4237 screened patients: Prevalence, development and management over 6 years
14. Abdominal aortic aneurysm screening: An epidemiological point of view
15. The case against a national screening programme for aortic aneurysms
16. Influence of screening on the incidence of ruptured abdominal aortic aneurysms: 5-year results of a randomized controlled study
17. Is screening once at age 65 an effective method for detection of abdominal aortic aneurysms?
18. Screening for abdominal aortic aneurysm: A single scan is enough
19. Pathogenesis of abdominal aortic aneurysms: A multidisciplinary research program supported by the National Heart, Lung, and Blood Institute
20. A lamellar unit of aortic medial structure and function in mammals
21. Comparison of abdominal and thoracic aortic medial structure in mammals: Deviation of man from the usual pattern
22. Nature of species differences in the medial distribution of aortic vasa vasorum in mammals
23. Relationship between hierarchical structure and mechanical properties of the arteries
24. Mechanical behavior of vascular smooth muscle in cylindrical segments of arteries in vitro
25. Mechanisms of arterial and aneurysmal tortuosity
26. Elastin, collagen, and the pathophysiology of arterial aneurysms
27. Elastin
28. The elastic fiber
29. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon
30. Control of elastin synthesis: Molecular and cellular aspects
31. Structure of the elastin gene and alternative splicing of elastin mRNA
32. Tropoelastin heterogeneity: Implications for protein function and disease
33. Deletion analysis of the 5′-flanking region of the human elastin gene: Delineation of functional promoter and regulatory cis-elements
34. The elastin receptor: A galactoside-binding protein
35. The elastin receptor shows structural and functional similarities to the 67-kDa tumor cell laminin receptor
36. 67-kD elastin-binding protein is a protective "companion" of extracellular insoluble elastin and intracellular tropoelastin
37. The 67-kDa enzymatically inactive alternatively spliced variant of beta- galactosidase is identical to the elastin/laminin-binding protein
38. Recycling of the 67-kDa elastin binding protein in arterial myocytes is imperative for secretion of tropoelastin
39. Impaired elastin fiber assembly related to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured aortic smooth muscle cells treated with chondroitin sulfate
40. Developmental regulation of elastin production. Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state mRNA levels
41. Novel arterial pathology in mice and humans hemizygous for elastin
42. Chemotactic activity of elastin-derived peptides
43. Chemotactic responses of fibroblasts to tropoelastin and elastin-derived peptides
44. Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes
45. Interaction between cells and elastin fibers: An ultrastructural and immunocytochemical study
46. Lymphocytes in human atherosclerotic plaque exhibit the elastin-laminin receptor: Potential role in atherogenesis
47. Nature and the multiple functions of the 67-kD elastin-/laminin-binding protein
48. Nuclear and cytoplasmic free calcium level changes induced by elastin peptides in human endothelial cells
49. + level in human vascular endothelial cells
50. Alignment of fibrillin molecules in elastic microfibrils is defined by transglutaminase-derived cross-links
51. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1
52. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1
53. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5
54. Molecular etiology, pathogenesis and diagnosis of the Marfan syndrome
55. Fibrillin-1 mutations in Marfan syndrome and other type-1 fibrillinopathies
56. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome
57. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1
58. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly
59. Fibrillin mutations in Marfan syndrome and related phenotypes
60. Ascending aortic aneurysm with or without features of Marfan syndrome and other fibrillinopathies: New insights
61. An association between arterial pulse pressure and variation in the fibrillin-1 gene
62. The protein components of the 12-nanometer microfibrils of elastic and nonelastic tissues
63. Complementary DNA cloning establishes microfibril-associated glycoprotein (MAGP) to be a discrete component of the elastin-associated microfibrils
64. Microfibril-associated glycoprotein binds to the carboxyl-terminal domain of tropoelastin and is a substrate for transglutaminase
65. Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2
66. Microfibril-associated glycoprotein-2 (MAGP-2) is specifically associated with fibrillin-containing micro-fibrils but exhibits more restricted patterns of tissue localization and developmental expression than its MAGP-1
67. The exon structure of the human MAGP-2 gene: Similarity with the MAGP-1 gene is confined to two exons encoding a cysteine-rich region
68. The biosynthesis of collagen and its disorders
69. The biosynthesis of collagen and its disorders
70. Collagen
71. Tensile strength and collagen in abdominal aortic aneurysm disease
72. Collagen biosynthesis
73. Procollagen N-proteinase and procollagen C-proteinase: Two unusual metalloproteinases that are essential for procollagen processing probably have important roles in development and cell signaling
74. Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples
75. Lysyl oxidase: Properties, regulation and multiple functions in biology
76. Lysyl oxidase, cellular senescence and tumor suppression
77. The family of collagen genes
78. Embryonic lethal mutation in mice induced by retrovirus insertion in the a1(I) collagen gene
79. Complex and diversified regulatory programs control the expression of vertebrate collagen genes
80. Molecular genetics of Marfan syndrome and Ehlers-Danlos type IV
81. The surgical complications of Ehlers-Danlos syndrome
82. Vascular mechanics
83. Influence of sympathetic stimulation on the mechanical properties of the aorta in humans
84. The reason for the shape of the distensibility curves of arteries
85. Sex difference in the mechanical properties of the abdominal aorta in human beings
86. Mechanical properties of arteries in vivo
87. The mechanical properties of the normal and aneurysmal abdominal aorta in vivo
88. Age dependent variations of elastin and elastase in aorta and human breast cancers
89. Histological changes in the normal aging aorta: Implication for dissecting aneurysms
90. Alterations with age in the visco-elastic properties of human arterial walls
91. The influence of age, arteriosclerosis and homotransplantation upon the elastic properties of major human arteries
92. Pathophysiology and pathogenesis of aortic aneurysms
93. Pressure amplitude increase and matching the aortic iliac junction of the dog
94. Elastolytic and collagenolytic studies of arteries: Implications for the mechanical properties of aneurysms
95. Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation
96. Aortic diameter as a function of age, gender, and body surface area
97. Infrarenal aortic diameter in the healthy person
98. Suggested standards for reporting on arterial aneurysms
99. Epidemiology of abdominal aortic aneurysm: The effect of differing definitions
100. The value of ultrasonography in the diagnosis of abdominal aortic aneurysm
101. Factors influencing enlargement rate of small abdominal aortic aneurysms
102. Oxford screening programme for abdominal aortic aneurysm in men aged 65 to 74 years
103. Relationship of age, gender, race, and body size to infrarenal aortic diameter
104. Arterial hemodynamics and wall mechanics
105. Fluid wall shear stress measurements in a model of the human abdominal aorta: Oscillatory behavior and relationship to atherosclerosis
106. Poststenotic dilatation
107. Aortic aneurysms as late sequelae of above-knee amputation
108. Differential patterns of atherosclerotic disease in patients with unilateral hemiparesis resulting from poliomyelitis: Case reports demonstrating the possible effect of hemodynamics
109. Compensatory enlargement of human atherosclerotic coronary arteries
110. Differential enlargement of artery segments in response to enlarging atherosclerotic plaques
111. Aneurysmal enlargement of the aorta during regression of experimental atherosclerosis
112. Aneurysm formation in experimental atherosclerosis: Relationship to plaque evolution
113. Familial abdominal aortic aneurysms
114. Fifty families with abdominal aortic aneurysms in two or more first-order relatives
115. Aneurysms of the abdominal aorta: Familial and genetic aspects in three hundred thirteen pedigrees
116. Search for aneurysm susceptibility gene(s)
117. Familial thoracic aortic aneurysms and dissections: Genetic heterogeneity with a major locus mapping to 5q13-14
118. Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder
119. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm
120. A mutation in the gene for type III procollagen (COL3A1) in a family with aortic aneurysms
121. Sequencing of cDNA from 50 unrelated patients reveals that mutations in the triple-helical domain of type III procollagen are an infrequent cause of aortic aneurysms
122. Genetic risk factor for abdominal aortic aneurysm: HLA-DR2(15), a Japanese study
123. Genetic risk factors in inflammatory abdominal aortic aneurysms: Polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element
124. Human abdominal aortic aneurysms: Immunophenotypic analysis suggesting an immune-mediated response
125. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm
126. Chronic inflammation and elastin degradation in abdominal aortic aneurysm disease: An immunohistochemical and electron microscopic study
127. An immunohistochemical study of inflammatory abdominal aortic aneurysms
128. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms
129. Monocyte chemotactic activity in human abdominal aortic aneurysms: Role of elastin degradation peptides and the 67-kD cell surface elastin receptor
130. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas
131. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms
132. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: The possible role for IL-6 and interferon-gamma in vascular inflammation
133. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms
134. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: Implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms
135. Medial neovascularization in abdominal aortic aneurysms: A histopathologic marker of aneurysmal degeneration with pathophysiologic implications
136. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression
137. Activation of human monocytes through CD40 induces matrix metalloproteinases
138. Inflammatory abdominal aortic aneurysm and the associated T-cell reaction: A case study
139. Interleukin-10 deficiency potentiates aortic collagen and elastin degradation in elastase-induced murine aortic aneurysm formation [abstract]
140. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4
141. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes
142. Features of autoimmunity in the abdominal aortic aneurysm
143. Partial amino acid sequence of a novel 40-kDa human aortic protein, with vitronectin-like fibrinogen-like, and calcium binding domains: Aortic aneurysm-associated protein-40 (AAAP-40) [human MAGP-3, proposed]
144. Unrestricted usage of immunoglobulin heavy chain genes in B cells infiltrating the wall of atherosclerotic abdominal aortic aneurysms
145. Analysis of the T cell receptor V beta repertoire in human aortic aneurysms
146. Infection and atherosclerosis: Focus on cytomegalovirus and Chlamydia pneumoniae
147. Infection and atherosclerosis: Emerging mechanistic paradigms
148. Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction
149. In situ detection of frequent and active infection of human cytomegalovirus in inflammatory abdominal aortic aneurysms: Possible pathogenic role in sustained chronic inflammatory reaction
150. Chlamydia pneumoniae in human abdominal aortic aneurysms
151. Failure to demonstrate Chlamydia pneumoniae in symptomatic abdominal aortic aneurysms by a nested polymerase chain reaction (PCR)
152. Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm
153. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms
154. Elastin degradation in abdominal aortic aneurysms
155. Histochemistry of aortic elastin in nonspecific abdominal aortic aneurysm disease
156. Dilatation through loss of elastin
157. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms
158. Collagenase activity of the human aorta: A comparison of patients with and without abdominal aortic aneurysms
159. Elastase activity: The role of elastase in aortic aneurysm formation
160. Characterization of human aortic elastase found in patients with abdominal aortic aneurysms
161. Metalloproteinases in degenerative aortic disease
162. Role of matrix metalloproteinases in abdominal aortic aneurysms
163. Metalloproteinases and their inhibitors in matrix remodeling
164. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
165. Matrix metalloproteinases: A review
166. Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation
167. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family
168. Activation mechanisms of matrix metalloproteinases
169. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: Implications for atherosclerotic plaque stability
170. Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain
171. Mechanism of cell surface activation of 72-kDa type IV collagenase: Isolation of the activated form of the membrane metalloprotease
172. Cell surface activation of progelatinase A (proMMP-2) and cell migration
173. Interstitial collagenases
174. Characteristics of the action of human skin fibroblast collagenase on fibrillar collagen
175. Matrix metalloproteinases in tissue repair
176. Human neutrophil collagenase: A distinct gene product with homology to other matrix metalloproteinases
177. Chondrocyte matrix metalloproteinase-8: Human articular chondrocytes express neutrophil collagenase
178. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: Regulation by tumor necrosis factor-alpha and doxycycline
179. Rat collagenase: Cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells
180. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
181. Biochemical characterization of human collagenase-3
182. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
183. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis
184. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13)
185. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors
186. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: A role in osteoarthritis
187. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation
188. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease
189. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta
190. Collagen stability and collagenolytic activity in the normal and aneurysmal human abdominal aorta
191. Inducible synthesis of collagenase and other neutral metalloproteinases by cells of aortic origin
192. Collagen in abdominal aortic aneurysm: Typing, content, and degradation
193. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms: Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms
194. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture
195. Human 92- and 72-kilodalton type IV collagenases are elastases
196. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: A quantitative comparison of the activities of 95 kDa and 75 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP)
197. Matrix metalloproteinase-2 is an interstitial collagenase: Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments
198. In situ localization and quantification of seventy-two-kilodalton type IV collagenase in aneurysmal, occlusive, and normal aorta
199. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture
200. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms
201. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms
202. Characterization of an elastase from aneurysmal aorta which degrades intact aortic elastin
203. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall
204. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm
205. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta
206. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages
207. Size matters: The relationship between MMP-9 expression and aortic diameter
208. Neutral metalloproteinases produced by human mononuclear phagocytes: Enzyme profile, regulation, and expression during cellular development
209. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases: Role of the fibronectin type II-like repeats
210. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms
211. Elevated plasma levels of matrix metalloproteinase-9 (MMP-9) in patients with abdominal aortic aneurysms: A circulating marker of degenerative aneurysm disease
212. Basic science of abdominal aortic aneurysms: Emerging therapeutic strategies for an unresolved clinical problem
213. Inflammation, metalloproteinases, and increased proteolysis: An emerging pathophysiological paradigm in aortic aneurysm
214. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9
215. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms
216. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme
217. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages
218. Human macrophage metalloelastase: Genomic organization, chromosomal location, gene linkage, and tissue-specific expression
219. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase
220. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice
221. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
222. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits
223. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree
224. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
225. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms
226. Regulation of matrix metalloproteinase gene expression
227. Neutral proteinase expression by human mononuclear phagocytes: A prominent role of cellular differentiation
228. Induction of macrophage metalloproteinases by extracellular matrix: Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms
229. Immune modulation of metalloproteinase production in human macrophages: Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma
230. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through phagocytes in vitro
231. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
232. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis
233. Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: A preliminary report
234. Expression and sequence of the gene for tissue inhibitor of metalloproteinases in patients with abdominal aortic aneurysms
235. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
236. Neutrophil chemotaxis and neutrophil elastase in the aortic wall in patients with abdominal aortic aneurysms
237. Role of the neutrophil in abdominal aortic aneurysm development
238. Role of serine proteases in aneurysm development
239. Nicotine-stimulated elastase activity release by neutrophils in patients with abdominal aortic aneurysms
240. Smooth muscle cell elastase, atherosclerosis, and abdominal aortic aneurysms
241. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms
242. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease
243. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: A possible mechanism for aneurysm expansion
244. Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta
245. Plasminogen activator and plasminogen activator inhibitor expression by normal and aneurysmal human aortic smooth muscle cells in culture
246. Activity and localization of cathepsin B, D and G in aortic aneurysm
247. Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus
248. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells
249. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms
250. Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms
251. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms
252. Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas
253. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms as compared to the adjacent inferior mesenteric artery
254. Mechanical wall stress in abdominal aortic aneurysm: Influence of diameter and asymmetry
255. Morphology of ruptured abdominal aortic aneurysms
256. Ultrasonic evaluation of abdominal aortic thrombus
257. Utility of computed tomography for surveillance of small abdominal aortic aneurysms: Preliminary report
258. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms
259. Intraluminal thrombus predicts rupture of an abdominal aortic aneurysm
260. Possible objectification of a critical maximum diameter for elective surgery in abdominal aortic aneurysms based on one- and three-dimensional ratios
261. Effect of intraluminal thrombus on abdominal aortic aneurysm wall stress
262. Biomechanics of abdominal aortic aneurysm in the presence of endoluminal thrombus: Experimental characterisation and structural static computational analysis
263. Potential influence of intraluminal thrombus on abdominal aortic aneurysm as assessed by a new non-invasive method
264. Effect of intraluminal thrombus thickness and bulge diameter on the oxygen diffusion in abdominal aortic aneurysm
265. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening
266. Strain-responsive regions in the platelet-derived growth factor-A gene promoter
267. Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress
268. Signal transduction in arteriosclerosis: Mechanical stress-activated MAP kinases in vascular smooth muscle cells
269. Mechanical strain of rat vascular smooth muscle cells is sensed by specific extracellular matrix/integrin interactions
270. Enhanced collagen production by smooth muscle cells during repetitive mechanical stretching
271. Relationship between abdominal aortic aneurysm wall compliance and clinical outcome: A preliminary analysis
272. Animal models of aneurysms
273. Experimental techniques and models in the study of the development and treatment of abdominal aortic aneurysm
274. Production of aortic aneurysms in turkeys and effect of various compounds in potentiating induced aortic ruptures
275. Age of onset, pattern of distribution and histology of aneurysm development in a genetically predisposed mouse model
276. BAPN-induced dissecting aneurysm of turkeys: Treatment with propranolol
277. Propranolol delays the formation of aneurysms in the male blotchy mouse
278. Elastase induced experimental aneurysms in rats
279. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysm
280. Experimental study of determinants of aneurysmal expansion of the abdominal aorta
281. Inflammatory aspects of experimental aneurysms: Effect of methylprednisolone and cyclosporine
282. Anti-CD18 monoclonal antibody slows experimental aortic aneurysm expansion
283. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat
284. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase
285. Hypertension accelerates the growth of experimental aortic aneurysms
286. Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model
287. The elastase infusion model of experimental aortic aneurysms: Synchrony of induction of endogenous proteinases with matrix destruction and inflammatory cell response
288. Sequential expression of metallogelatinases during elastase-induced aneurysmal degeneration of the rat aorta: Correlations with aortic dilatation and the destruction of medial elastin
289. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: Preservation of aortic elastin associated with suppressed production of 92 kD gelatinase
290. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms
291. Pharmacologic suppression of experimental abdominal aortic aneurysms: A comparison of doxycycline and four chemically modified tetracyclines
292. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms
293. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908)
294. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms
295. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors
296. Hemodynamics and aneurysm development in vascular allografts
297. Cell-free arterial grafts: Morphologic characteristics of aortic isografts, allografts, and xenografts in rats
298. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model
299. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1
300. Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model
301. Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor RS-113,456
302. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development
303. Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis
304. The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: Development of lesions and morphometric analysis
305. Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice That overproduce angiotensin II
306. Ongoing viral replication is required for gammaherpesvirus 68-induced vascular damage
307. IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site
308. Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride in vivo
309. Murine aortic aneurysm produced by periarterial application of calcium chloride
310. MMP-9 knockout mice are resistant to calcium chloride aneurysm induction
311. Aneurysm induction in mice deficient in metalloproteinase 9 or 12
312. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice
313. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
314. Experimental abdominal aortic aneurysms in mice lacking expression of inducible nitric oxide synthase
315. Variables that affect the expansion rate and outcome of small abdominal aortic aneurysms
316. Smoking and growth rate of small abdominal aortic aneurysms
317. The nitrite/elastin reaction: Implications for in vivo degenerative effects
318. Statins do more than just lower cholesterol
319. Inhibition of monocyte chemotactic protein-1 synthesis by statins
320. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome
321. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms
322. Abdominal aortic aneurysm expansion rate: Effect of size and beta-adrenergic blockade
323. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms
324. Matrix metalloproteinases and their inhibition in periodontal treatment
325. Potential of tetracyclines to modify cartilage breakdown in osteoarthritis
326. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis
327. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms
328. Therapeutic potential of tetracycline derivatives to suppress the growth of abdominal aortic aneurysms
329. MMP inhibition in abdominal aortic aneurysms: Rationale for a prospective randomized clinical trial
330. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (phase II) multicenter study
331. Selective screening for abdominal aortic aneurysms with physical examination and ultrasound
332. Management of small abdominal aortic aneurysms: Early surgery vs watchful waiting
333. Late abdominal aortic aneurysm rupture after AneuRx repair: A report of three cases
334. Aneurysm rupture after endovascular repair using the AneuRx stent graft
335. Algorithm for the diagnosis and treatment of endoleaks
336. Surveillance of patients after abdominal aortic aneurysm repair with endovascular grafting or conventional treatment
337. Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms
338. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm
339. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation
340. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms
341. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms: A preliminary study
342. Reduction in aortic aneurysm size: Early results after endovascular graft placement
343. Simultaneous analysis of 1176 gene products in normal human aorta and abdominal aortic aneurysms using a membrane-based complementary DNA expression array
344. In vivo three-dimensional surface geometry of abdominal aortic aneurysms
345. New imaging techniques in endovascular surgery
346. Wall stress distribution on three-dimensionally reconstructed models of human abdominal aortic aneurysm
347. Fibulin-2 exhibits high degree of variability, but no structural changes concordant with abdominal aortic aneurysms
348. Analysis of coding sequences for tissue inhibitor of metalloproteinases 1 (TIMP1) and 2 (TIMP2) in patients with aneurysms
349. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms